Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-17
2006-10-17
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S094630, C435S183000, C435S220000
Reexamination Certificate
active
07122514
ABSTRACT:
Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans ofstaphylococcicell walls such as lysostaphin and an antibiotic effective againststaphylococcidue to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, evenstaphylococcithat may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include β-lactams and glycopeptides.
REFERENCES:
patent: 3278378 (1966-10-01), Schindler et al.
patent: 3398056 (1968-08-01), Zygmunt et al.
patent: 3594284 (1971-07-01), Zygmunt et al.
patent: 4931390 (1990-06-01), Recsei
patent: 5760026 (1998-06-01), Blackburn et al.
patent: 5858962 (1999-01-01), Blackburn et al.
patent: 6028051 (2000-02-01), Climo et al.
Craven et al. J. Vet. Pharmacol. Therap, 221-226, 1980.
The Staphylococci in Human Disease. Chapter 26. pp. 583-595: Henry F. Chambers. “Parenteral Antibiotics for the Treatment of Bacteremia and Other Serious Staphylococcal Infections”.
Diagn Microbiol Infect. Dis., 1993; 17:265-70. Polak, et al., “In Vitro Activity of Recombinant Lysostaphin-Antibiotic Combinations Toward Methicillin-ResistantStaphylococcus aureus”.
The Staphylococci in Human Disease. Chapter 6 (part 2). pp. 158-174, Brigitte Berger-Bachi. Resistance Not Mediated By β-Lactamase (Methicillin Resistance).
FEMS Microbiology Letters. 153 (1997) pp. 261-264, Tschierske et al., “Lif. the Lysostaphin Immunity Factor. Complements Femβ in Staphylococcal Peptidoglycan Interpeptide Bridge Formation”.
Applied and Environment Microbiology, Apr. 1995. pp. 1475-1479. DeHart et al., “The Lystostaphin Endopeptidase Resistance Gene (cpr) Specifies Modification of Peptidoglycan Cross Bridges inStaphylococcus simulansandStaphylococcus aureus”.
Journal of Bacteriology. Jan. 1997. pp. 9-16. Stranden et al., “Cell Wall Monoglycine Cross-Bridges and Methicillin Hypersusceptibility in a Femβ Null Mutant of Methicillin-ResistantStaphylococcus aureaus”.
Canadian Journal of Microbiology, vol. 13 (1967). pp. 845-853. Zygmunt et al., “Lytic Action of Lysostaphin on Susceptible and Resistant Strains ofStaphylococcus aureus”.
Journal of Bacteriology, Dec. 1997. pp. 7573-7576. No. 23. Ehlert et al., “Specificities of FemA and Femβ for Different Glycine Residues: Femβ Cannot Substitute for FemA in Staphylococcal Peptidoglycan Pentaglycine Side Chain Formation”.
Lystostaphin-Methicillin Therapy. vol. 41. Aug. 1968. pp. 62-68. Goodman et al., “Lysostaphin: An Anzymatic Approach to Staphylococcal Disease”.
Yale Journal of Biology and Medicine. vol. 39. Feb. 1967. pp. 230-244. Schaffner et al., “Lysostaphin: An Enzymatic Approach to Staphylococcal Disease”.
Kessler et al., “Secreted LasA ofPseudomonasaeruginosa Is a Staphylolytic Protease”. Journal of Biological Chemistry. vol. 268. No. 10. pp. 7503-7508 (1993).
Li et al., “Purification. Staphylolytic Activity. and Cleavage Sites of α-Lytic Protease fromAchromobacter lyticus”. The Journal of Biological Chemistry. vol. 122. No. 4, pp. 772-778 (1997).
Oldham et al., “Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis Therapeutic”., J. Diary of Sci., 74:4175-82 (1991).
Martin et al., “The Selective Activity of Lysotaphin in vivo”. The Journal of Laboratory and Clinical Medicine. vol. 70. No. 1, pp. 1-8 (Jul. 1967).
Martin et al., “The Reacquisition of Staphylococci by Treated Carriers: A Demonstration of Bacterial Interference”. J. Lab. Clin. Med., vol. 71. No. 5, pp. 791-797 (May 1968).
Harrison et al., “Therapeutic Activity of Lysostaphin in Experimental Staphylococcal Infections”. Canadian Journal of Microbiology. vol. 13. pp. 93-97 (1967).
Schuhardt et al., “Lysostaphin Therapy in Mice Infected withStaphylococcus aureus.” J. Bacteriol., vol. 88. No. 1064. pp. 815-816.
Stark et al., Systemic Lysostaphin Man-Apparent Antimicrobial Activity in A Neutropenic Patient. The New England Journal of Medicine. pp. 239-240 (Aug. 1974).
Goldberg et al., “Studies in Experimental Staphylococcal Endocarditis in Dogs. VI. Treatment in Lysostaphin”. Antimicrobial Agents and Chemotherapy, pp. 45-53 (1967).
Quickel Jr. et al., “Efficacy and Safety of Topical Lysostaphin Treatment of Persistent Nasal Carriage ofStaphylococcus aureus”, Applied Microbiology, pp. 446-450 (Sep. 1971).
Harrison et al., “Lysostaphin in Experimental Renal Infections”. Journal of Bacteriology. pp. 520-524. (Feb. 1967).
Archer Gordon
Climo Michael
Murphy Ellen
Borin Michael
Kelber Steven B.
Merchant & Gould P.C.
Nutrition 21, Inc.
LandOfFree
Compositions and methods for treatment of staphylococcal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of staphylococcal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of staphylococcal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677717